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Artificial Sweetener Use and Bladder Cancer: 
A Case-Control Study 
Abstract. In a case-control study of 302 male and 65 female bladder cancer pa-
tients and an equal number of other patients matched to them in age, SeX, hospital, 
and hospital-room status, no {Issociatian was found between use of artificial sweet-
el1ers or diet beverages and bladder cancer. No dose-response was observed with 
respect to quantity or duration of use or the two combined. No evidence was found to 
suggest that artificial sweeteners or diet beverages promote the tumorigenic effect of 
tobacco smoking. Artificial sweetner and diet beverage use strongly reflected so-
cioeconomic status among controls with various diagnoses. 
The relation between saccharin and 
bladder cancer in humans is a matter of 
both public and scientific controversy, 
extending even into the arena of legisla-
tive debate and regulatory processes. 
Experimental and epidemiological evi-
dence to date has provided contradictory 
results. Several feeding studies have 
demonstrated a statistically significant 
increase in bladder tumors in male rats 
(1), and tumor-promoting effects have 
been observed in vitro (2) and in vivo (3). 
Published epidemiological studies have 
been uniformly negative (4), except for 
one in which an increased risk was re-
ported for males only (5). 
We present here data on the relation 
between artificial sweetener (AS) and 
diet beverage (DB) use and bladder can-
cer collected in an ongoing case-control 
study of smoking and disease (6-8) by 
means of interviews of patients in hos-
pitals in New York and several other 
cities. Cases eligible for the present 
study were 312 male and 79 female pa-
tients admitted with a first diagnosis of 
bladder cancer who were interviewed 
between August 1977 and June 1979. The 
population from which the controls were 
drawn consisted of 3798 male and 1799 
female patients admitted for other condi-
tions, neoplastic and nonneoplastic (9), 
and interviewed in the same period. All 
diagnoses were verified histopathologi-
cally. 
The interviews were conducted in the 
hospitals by professional interviewers. 
Data were obtained on a variety of de-
mographic variables and on the use of to-
bacco, alcohol, coffee, tea, and other 
beverages, including those containing ar-
tificial sweeteners. 
Comparison of background variables 
indicated, as in our previous studies, that 
the male bladder cancer cases tended to 
be of much higher professional and edu-
cationallevels than the males in the con-
trol pool and the female cases were much 
lower than female controls (10). A sub-
stantial proportion in the control pool 
had diseases linked to lower socioeco-
momic background, especially cancer of 
the lung, the larynx, and the mouth (7, 
1 I). Several variables indicative of so-
cioeconomic level were strongly associ-
ated with both AS and DB use. There-
fore a subset of controls was chosen (by 
computer) which matched the cases on a 
one-to-one basis not only in age (in dec-
ades) and sex but also in hospital and 
hospital-room status (private, semipri-
vate, or ward), these being found to be 
an excellent indicator of socioeconomic 
status. Matches were found for all but 10 
Table I. Regular users of artificial sweeteners and diet beverages among bladder cancer patients 
and matched controls. Regular use was defined as continued use for at least 1 month. The 
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male and 14 female cases. The diagnoses 
of the male matched controls were to-
bacco-related cancers (lung, larynx, 
mouth, and esophagus), 23 percent; oth-
er cancers, 38 percent; benign neoplastic 
diseases, 5 percent; and nonneoplastic 
conditions, 34 percent. Among the wom-
en the corresponding figures were 14, 36, 
7, and 43 percent. 
The quantity of regular AS intake (12) 
is reported here in terms of units per day, 
a unit being roughly equal to 20 to 40 mg 
of saccharin, depending upon which 
commercial product is used; no attempt 
was made to identify dosages more pre-
cisely. Canned diet beverages usually 
contain 8 to 11 mg of saccharin per 
ounce. The unit of DB consumption was 
taken to be a 12-ounce can, that being 
the most popular size. Information on 
use of diet foods was not obtained (13). 
Among males, 25.2 percent of the cas-
es and 26.5 percent of the matched con-
trols reported current or past regular use 
of AS; among females, 21.5 percent and 
29.2 percent (Table 1). Among male 
users, more controls than cases (43 per-
cent versus 25 percent, P < .05) were or 
had been heavy (4+ units a day) AS 
users; no other statistically significant 
differences in duration or amount were 
found between cases and controls of ei-
ther sex (Tables 2 and 3). 
Of particular interest are those who 
used AS or DB in large quantities for 
long periods of time. If AS enhances car-
cinogenesis in the bladder, then these 
persons should be overrepresented 
among the cases. We classified AS users 
as either having or not having consumed 
at least 2 units per day for at least 10 
years. There were no statistically signifi· 
cant differences between cases and con-
trols classified on this measure or on an 
analogous DB measure. 
We computed the average quantity 
and duration of AS usage for cases and 
controls, as well as the mean of the prod-
uct of quantity (units per day) and dura-
tion of use in years as a measure of cu-
mulative dose. There were no statistical-
ly significant differences between cases 
and controls for any of these variables. 
We also attempted to quantify lifetime 
AS intake, estimated as grams of saccha-
rin, with a composite AS and DB mea-
sure. For this calculation, the lifetime 
saccharin consumption for each regular 
user of AS or DB was estimated as (AS 
units per day x 30 mg x 365 x years 
of AS use) + (DB cans per week x 110 
mg x 52 x years of DB use). The life-
time saccharin intake estimated in this 
way was about 20 percent lower for ca-
ses than for controls (408 g for male cas-
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Table 2. Quantity of artificial sweeteners (per day) and diet bever- Table 3. Duration of regular use of artificial sweeteners and diet bev-
ages (per week) used regularly by bladder cancer patients and erages by bladder cancer patients and matched controls. 
matched controls. Artificial sweeteners are estimated in units of 20 
to 40 mg'of saccharin, diet beverages in 12-ounce cans or equivalent Males (%) Females (%) (see text). 
Number 
Number Males (%) Females (%) of Cases Con- Cases Con-
of years (N trois (N = trois Cases Controls Cases Controls (N = (N units (N 302) (N '" 302) (N = 65) (N 65) 302) 302) 65) 65) 
Artificial sweeteners Artificial sweeteners 
None 74.8 73.5 78.5 70.8 None 74.8 73.5 78.5 70.8 
<I aday 1.0 1.7 6.1 1-4 10.3 10.3 9.2 12.3 
I 8.3 5.6 7.7 10.8 5-9 6.3 8.9 4.6 4.6 
2 6.6 7.0 3.1 3.1 10 4.3 2.6 4.6 3.1 
3 3.0 1.7 3.1 3.1 11-15 2.0 1.3 3.1 4.6 
4 1.0 4.3 4.6 16+ 2.3 2.6 4.6 
5-10 3.3 4.3 1.5 3.1 Not stated 0.7 
11+ 2.0 1.0 1.5 3.1 Diel beverages Not stated 1.0 None 1:15.1 82.8 84.6 75.4 
Diet beverages <I 0.3 3.1 
None 85.1 82.8 84.6 75.4 1-4 5.3 6.0 7.7 12.3 
<1 a week 3.1 5 0.7 3.3 1.5 3.1 
1-3 6.3 5.3 9.2 10.8 6-9 1.3 2.0 1.5 
4-7 5.3 8.3 4.6 6.2 10 4.6 2.3 1.5 4.6 
8-14 1.3 2.0 4,6 11-15 2.3 2,6 3,1 1.5 
15-21 1.3 0.7 16+ 0.3 0.3 
22+ 0.7 1.0 1.5 Not stated 0.3 0.3 
-~~------.--~.----~.---.--.--. 
es, 496 g for male controls; 372 g for fe-
male cases, 455 g for female controls). 
The differences were not statistically sig-
nificant. 
Risk ratios (RR) for bladder cancer 
among AS and DB consumers (Table 4) 
were estimated by the matched-pair pro-
cedure described by Miettinen (14). No 
changes of any substance were produced 
by differentiating current and former 
users. The RR (and 95 percent con-
fidence interval) among men was 0.93 
(0.68-1.28) for AS and 0.85 (0.55-1.17) 
for DB, and among women 0.62 (0.26-
lAO) and 0.60 (0.27-1.29), respectively. 
The RR estimates did not vary appre-
ciably when further controlled for a num-
ber of potentially confounding variables, 
such as history of diabetes, obesity, oc-
cupation, education, religion, and coffee 
or tea consumption (15). 
The possibility that AS piays the role 
of a promoter rather than a primary car-
cinogen was investigated by computing 
RR's by the Mantel-Haenszel method 
(16) for subjects who were cunent long-
term (:2': 10 years) smokers of cigarettes 
(17). In men theRR was 0.56 (0.29-1.09), 
in women 1.04 (0.21-5.09); similar re-
sults were obtained for DB. No statisti-
cally significant changes occurred when 
smokers were further classified by the 
number of cigarettes smoked per day. 
For completeness, the association be-
tween cigarette smoking and bladder 
cancer was examined, as in our previous 
studies (6,7), by estimatingRR's among 
present smokers relative to nonsmokers. 
For men the RR was 2.53 (P < .001); for 
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women 2.19 (P"" .05). These estimates 
are probably somewhat low because of 
inclusion of controls with tobacco-re-
lated cancers, but they are consistent 
with our previous reports. 
It is possible, of course, that the ab-
sence of a demonstrable association in 
our data between AS or DB use and 
bladder cancer is due to insufficient 
sample size. At levels of 5 percent signif-
icance and 80 percent power, and with 
an AS usage rate of25 percent among the 
male controls, the minimum RR detect-
able with the given sample size is about 
1.5 (18). For women the corresponding 
figure is about 2.8. The estimated RR's 
are not significantly different from 1, but 
the upper limits of their 95 percent con-
fidence intervals are 1.28 (men) and 1.40 
(women). However, the lack of a dose-
response in this study and the repeated 
findings of a negative association be-
tween AS or DB consumption and blad-
der cancer in women in t...'lJis and other 
studies (4-6) are inconsistent with a 
causal hypothesis, as is the low bladder 
cancer rate among diabetics (19), a group 
which consumes large quantities of sac-
charin. Furthermore, while we found 
obesity to be a major correlate of AS 
and DB use, obesity has never been 
reported as a risk factor for bladder 
cancer (20). 
The often-raised question of the risk 
for children, especially those exposed in 
utero, is not addressed here, nor can we 
assess risks for older persons with life-
long DB use, because these high-saccha-
rin products have not been on the market 
sufficiently long. Furthermore, because 
of the wide variation of saccharin con-
sumption observed among patients with 
Table 4. Matched-pair comparisons of use of artificial sweeteners and diet beverages by bladder 
cancer patients and controls. RR, risk ratio; ('1., confidence interval. 




Never used 61 
RR 57/61 0.93 
95 percent CI 0,68-1.28 
Used 6 
Never used 46 
RR = 39/46 0.85 







57 Used 6 
165 Never used 13 . 
RR = 8/13 0.62 
95 percent CI 0.26-1.40 
Diet beverages 
39 Used 1 
211 Never used 15 
RR 9/15 0.60 








various types of cancers, surveillance of 
AS and DB usage in hospital populations 
should be continued. 
ERNST L. WYNDER 
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American Health Foundation, 
320 East 43 Street, 
New York 10017 
Refilrences and NoteS 
I. Wisconsin Alumni Research Foundation, Lang 
Term Saccharin Feeding in Rats, Final Report 
(WARF, Madison, Wis., 1973); Division of Pa-
thology, Food and Drug Administration, Sub· 
acute and Chronic Toxicity and Carcinogenicity 
of Various Dose Levels of Sodium Saccharin, 
Final Report (Government Printing Office, 
Washington, D.C., (973), pp. 169-170; D. L. Ar-
nold, C. A. Moodie, N. C. Grice, S. M. Char-
bonneau, B. Stavric, B. T. Collins, P. F. 
McGuire, L C. Munro, Long Term Toxicity of 
Orthotoluenesulfonamide and Sodium Saccha-
rin in Ihe Ral: An Interim Report (Toxicology 
Research Division, Health Protection Bmnch, 
National Health and Welfare Ministry, Ottawa, 
Canada, 1977). 
2. S. Mondal, D. W. Brankow, C. Heidelberger, 
Science 201, 1141 (1978). 
3. R. M. Hicks, J. Chowaniec, J. St. J. Wakefield, 
in Mechanisms of Tumour Promotion and Co-
carcinogenesis, T. Slaga, Ed. (Raven, New 
York, 1978), vol. 2, p. 475; S. M. Cohen, M. 
Anu, J. B. Jacobs, G. M. Friedell, Cancer Res. 
39, 1207 (1979). 
4. D. Simon, S. Yen, P. Cole,J. Natf. Cancer Inst. 
54, 587 (1975); R. W. Morgan and M. G. Jain, 
Call. Med. Assoc. J. 111, 1067 (1974); 1. L Kes-
sler, J. Ural. 115, 143 (1976); __ and J. P. 
Clark, J. Am. Med. Assoc. 240, 349 (1978). 
5. G. R. Howe, J. D. Burch, A. B. Miller, B. Mor-
rison, P. Gordon, L. Weldon, L. W. Chambers, 
G. Fodor, G. M. Winsor, Lancet 1977-ll, 578 
(1977); A. B. Miller and G. R. Howe, ibid.,p. 1221. 
6. E. L. Wynder and R. Goldsmith, Callcer 40, 
1246 (1977). 
7. E. L. Wynder and S. D. Stellman, Callcer Res. 
37, 4608 (I 977). 
8. __ J. Natl. Cancer Insl. 62,471 (1979). 
9. Nonneoplastic tobacco-related diseases eligible 
for interview are myocardial infarction, abdomi-
nal aortic aneurysm, peripheral vascular dis· 
ease, chronic obstructive pUlmonary disease, 
chronic bronchitis, emphysema, gastric ulcer, 
and cirrhosis of the liver. In addition, many oth· 
er nonneoplastic diseases are eligible as control 
diagnoses, including fractures, burns, iofec-
tions, cataracts, surgical procedures, and so 
forth. 
10. This apparent selection bias for males is likely to 
be due in part to the relative difficulty of treat-
ment of bladder cancer, and the tendency of pa-
tients in higher socioeconomic str-... ta to be re-
ferred to specialized hospitals, such as Memo-
rial Hospital in New York, for primary care. 
Il. Proper interpretation of the data requires judg-
ment as to whether bias in selection of control 
patients has been minimized and confounding 
reduced. The extent to which confounding fac· 
tors are associated with the exposure of interest 
and also differ among cases and controls may 
profoundly influence estimates of association 
between exposure and disease. Both AS and DB 
use were strongly associated with socioeconom-
ic status indicators such as occupation level (27 
percent of professionals used AS compared to 
12 percent of unskilled workers) and higher edu-
cation (26 percent of college graduates used AS 
compared to 16 percent of those without high 
school). AS use was also greater among ex-
smokers than smokers, owing partly to the high-
er degree of education among ex-smokers (and 
possibly to their fear of weight gain), but was 
low among heavy consumers of alcohol, users of 
nonfilter cigarettes, and male ward patients; 
among female ward patients AS use was higher, 
owing pOssibly to the greater level of obesity in 
this group. 
12. Regular use was defined as continued use for at 
least one month. The reported frequency of 
"regular" AS or DB use lasting less than one 
year was < 1 percent. 
13. Questions were also asked abou t use of cy· 
clamates, which, in combination with saccharin, 
were contained in nearly all artificial sweeteners 
between 1960 and 1%9. Saccharin has been the 
only AS permitted by federal law since the ban-
1216 
ning of cyclamates as a carcinogen in 1%9. The 
number of subjects specifically recalling cy· 
clamate use, as distinct from saccharin, was too 
small for analysis. However, since cyclamates 
would have been used by nearly all who used AS 
for 10 years or more, and since no increased 
bladder cancer risk was observed among this 
group, it is highly unlikely that cyclamate con-
sumption contributed to excess cancer risk in 
our study population. 
14. O. S. Miettinen, Biometrics 60, 75 (1970). 
15. Exclusion of patients with diabetes from the 
analysis resulted in negligible lowering of RR's. 
Exclusion of patients with cardiovascu1ar dis-
eases also resulted in trivial changes; patients 
with cardiovascular disease in our study did not, 
as has often been suggested, consume larger 
amounts of AS or DB than other groups of 
controls. 
These findings are essentially in agreement 
with results obtained during an earlier phase of 
the study, in which a less elaborate question-
naire was used. In that version, three questions 
(history ofregular AS use [yes or no}, quantity, 
duration) were added in 1974 to a bladder cancer 
study already in progress, in response to wide-
spread public interest in possible health effects 
of saccharin. That stndy, published in 1977 (6), 
found no association between AS and bladder 
cancer based on the rather limited numbers then 
available: 132 male and 31 female cases and 
equal numbers of matched controls. As data col-
lection proceeded, an interim, preliminary anal-
ysis was submitted in a progress report to the 
National Cancer Institute in October 1917, 
based on 260 male and 86 female patients with 
bladder cancer. It gave crude RR estimates of 
1.87 for males and 0.9 for females. Reservations 
were expressed at the time that a causal hypoth-
esis might not be supported by the data for sev-
eral reasons: (i) Substantial socioeconomic dif-
ferences existed between cases and controls, 
with 29 percent of all male controls coming from 
Veterans Administration and county hospitals 
(notably Los Angeles County) compared with 
only 8 percent of male cases; opposite patterns 
of socioeconomic confounding appeared to ex-
plain much of the opposite female RR estimates. 
(ii) For a given substance to produce opposite 
risks for men and women would be highly Un-
usual. (Ui) RR estimates varied substantially 
from one city to another. 
When data collection terminated in 1977, 
bladder cancer cases numbered 402 males and 
122 females, with 7200 male and 3m female 
controls. Final crude RR estimates (and 95 per-
cent confidence intervals) were 1.85 (1.45-2.36) 
for males and 0.99 (0.61-1.59) for females. When 
adjusted for age, hospital, hospital-room status, 
and year of interview, these RR's feU to 1.43 
(J.lO--I.86) and 0.89 (0.48-1.64), respectively. A 
matched-pair analysis, with matching based on 
the above variables plus education, further reo 
duced the RR estimates to the statistically not 
significant values of L13 (0.60-2.09) and 0.80 
(0.20-2.98). An equivalent result was obtained 
by matching on occupation instead of education. 
There were no noteworthy or statistically signif-
icant differences between cases and controls 
with respect either to quantity or duration of AS 
use. 
16. N. Mantel and W. Haenszel, 1. NaIL. Cancer 
Insl. 22,719 (1959). 
17. All cigarette smokers interviewed had smoked 
for at least IO years. 
18. S. D. Walter,Am. J. Epidemiol. 105,387 (1977). 
The tables in this reference refer strictly to un-
matched studies; for matched pairs of cases and 
controls, the least significant risks are slightly 
smaller. 
19. I. I. Kessler, J. Natl. Catlcer Inst. 44, 673 
(1970); B. Armstrong and R. Doll, Br. J. Prevo 
Soc. Med. 28, 233 (1974). 
20. An additional observation of a strong associa-
tion between obesity and kidney cancer in both 
men and women leads to the prediction that 
these patients use substantial amounts of AS. 
Use of AS was in fact higher in the current series 
of 6S male kidney cancer patients, but not 
among the 88 male kidney cancer patients inter· 
viewed in 1974-1977. This epidemiological lead 
merits further investigation. 
21. Supported by contract NOI-CP-55666 and grant 
CA-17613 from the National Cancer Institute 
and by grant RD-48 from the American Cancer 
Society. Computations were performed in part 
at the Department of Energy Mathematics and 
Computing Laboratory, Courant Institute for 
Mathematical Sciences, supported by DOE con-
tract EY76-C-02-3077 at New York University, 
New York. The late Jerome Cornfield pro-
vided valuable counsel throughout this in-
vestigation. We thank E. Cuyler Hammond for 
critically reviewing the manuscript. 
4 October 1979; revised 5 December 1979 
SCIENCE, VOL. 207, 14 MARCH 1980 
